Effects of kappa opioid agonists alone and in combination with cocaine on heart rate and blood pressure in conscious squirrel monkeys

European Journal of Pharmacology

Volumn 576, Issue 1-3, 2007, Pages 107-113

  Schindler, Charles W ^a   Graczyk, Zofi ^a   Gilman, Joanne P ^a   Negus, S Stevens ^b   Bergman, Jack ^b   Mello, Nancy K ^b   Goldberg, Steven R ^a  

^a DHHS   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

(Squirrel monkey); Blood pressure; Cocaine; Heart rate; Kappa opioid

Indexed keywords

3 [1 (3,4 DICHLORO N METHYLPHENYLACETAMIDO) 2 (1 PYRROLIDINYL)ETHYL]PHENOXYACETIC ACID; COCAINE; ENADOLINE; ETHYLKETAZOCINE; NALTREXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE MEASUREMENT; COCAINE DEPENDENCE; CONSCIOUSNESS; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; HEART RATE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SQUIRREL MONKEY;

ANIMALS; BENZOFURANS; BLOOD PRESSURE; COCAINE; COCAINE-RELATED DISORDERS; DRUG INTERACTIONS; ETHYLKETOCYCLAZOCINE; HEART RATE; MALE; PYRROLIDINES; RECEPTORS, OPIOID, KAPPA; SAIMIRI;

EID: 35348953822     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.07.053     Document Type: Article

References (39)

1. Archer S., Glick S.D., and Bidlack J.M. Cyclazocine revisited. Neurochem. Res. 21 (1996) 1369-1373
2. Barber A., Bartoszyk G.D., Greiner H.E., Mauler F., Murray R.D., Seyfried C.A., Simon J., Gottschich R., Harting J., and Lues I. Central and peripheral actions of the novel K{green}-opioid receptor agonist, EMD 60400. Br. J. Pharmacol. 111 (1994) 843-851
3. Bellissant E., Denolle T., Sinnassamy P., Bichet D.G., Giudicelli J.F., Lecoz F., Gandon J.M., and Allain H. Systemic and regional hemodynamic and biological efects of a new kappa-opioid agonists, niravoline, in healthy volunteers. J. Pharmacol. Exp. Ther. 278 (1996) 232-242
4. Berger B., Rothmaier A.K., Wedekind F., Zentner J., Feuerstein T.J., and Jackisch R. Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex. Br. J. Pharmacol. 148 (2006) 795-806
5. Bowen C.A., Negus S.S., Zong R., Neumeyer J.L., Bidlack J.M., and Mello N.K. Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology 28 (2003) 1125-1139
6. Carey G.J., and Bergman J. Enadoline discrimination in squirrel monkeys: effects of opioid agonists and antagonists. J. Pharmacol. Exp. Ther. 297 (2001) 215-233
7. Ensinger H., Hedler L., Schurr C., and Starke K. Ethylketocyclazocine decreases noradrenaline release and blood pressure in the rabbit at a peripheral opioid receptor. Naunyn-Schmiedeberg's Arch. Pharmacol. 328 (1984) 20-23
8. Gautret B., and Schmitt H. Central and peripheral sites for cardiovascular actions of dynorphin-(1-13) in rats. Eur. J. Pharmacol. 111 (1985) 263-266
9. Hake D.F., and Azrin N.H. An apparatus for delivering pain shock to monkeys. J. Exp. Anal. Behav. 6 (1953) 297-298
10. Hassen A.H., Feuerstein G., and Faden A.I. Differential cardiovascular effects mediated by mu and kappa opiate receptors in hindbrain nuclei. Peptides 4 (1983) 621-625
11. Herd J.A., Morse W.H., Kelleher R.T., and Jones L.G. Arterial hypertension in the squirrel monkey during behavioral experiments. Am. J. Physiol. 217 (1969) 24-29
12. Herz A. Opioid reward mechanisms: a key role in drug abuse?. Can. J. Physiol. Pharm. 76 (1998) 252-258
13. Hunter J.C., Leighton G.E., Meecham K.G., Boyle S.J., Horwell D.C., Rees D.C., and Hughes J. CI-977, a novel and selective agonist for the k-opioid receptor. Br. J. Pharmacol. 101 (1990) 183-189
14. Husbands S.M. Kappa-opioid receptor ligands. Expert Opin. Ther. Pat. 14 (2004) 1725-1741
15. Kannan M.S., and Seip A.E. Neurogenic dilatation and constriction of rat superior mesenteric artery in vitro: mechanisms and mediators. Can. J. Physiol. Pharm. 64 (1986) 729-736
16. Krumins S.A., Faden A.I., and Feuerstein G. Opiate binding in rat hearts: modulation of binding after hemorrhagic shock. Biochem. Biophys. Res. Commun. 127 (1985) 120-128
17. Laurent S., and Schmitt H. Central cardiovascular effects of K{green} agonists dynorphin-(1-13) and ethylketocyclazonine in the anesthetized rat. Eur. J. Pharmacol. 96 (1983) 165-169
18. Leander J.D. Effects of ketazocine, ethylketaocine and phenazocine on schedule-controlled behavior: antagonism by naloxone. Neuropharmacology 21 (1982) 923-928
19. Li J., Li J.G., Chen C., Zhang F., and Liu-Chen L.Y. Molecular basis of differences in (-)(trans)-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidiny)-cyclohexyl]benzene acetamide-induced desensitization and phosphorylation between human and rat kappa-opioid receptors expressed in Chinese hamster ovary cells. Mol. Pharmacol. 61 (2002) 73-84
20. Maeda S., Nakamae J., and Inoki R. Positive inotrophic action of kappa opiate agonists, ethylketocyclazocine and dynorphin-A(1-13), in isolated rat atrium. Jpn. J. Pharmacol. 45 (1987) 125-128
21. Mansour A., Khachaturian H., Lewis M.E., Akil H., and Watson S.J. Anatomy of CNS opioid receptors. Trends Neurosci. 11 (1988) 308-314
22. Martin W.R. Pharmacology of opioids. Pharmacol. Rev. 35 (1984) 283-323
23. Mello N.K., and Negus S.S. Interactions between kappa opioid agonists and cocaine: preclinical studies. Ann. N.Y. Acad. Sci. 909 (2000) 104-132
24. Mello N.K., Mendelson J.H., Sholar M.B., Jaszyna-Gasior M., Goletiani N., and Siegel A.J. Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology 30 (2005) 618-632
25. National Research Council. Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (2003), National Academy Press, Washington, DC
26. Punnen S., and Sapru H.N. Cardiovascular responses to medullary microinjections of opiate agonists in urethane-anesthetized rats. J. Cardiovasc. Pharmacol. 8 (1986) 950-956
27. Riviere P.J. Peripheral kappa-opioid agonists for visceral pain. Br. J. Pharmacol. 141 (2004) 1331-1334
28. Rochford J., Godin C., and Henry J.L. Intrathecal administration of dynorphin A and its fragments increase heart rate and arterial pressure in the urethane anesthetized rat: mediation by a nonopioid mechanism. Brain Res. 565 (1991) 67-77
29. Rusovici D.E., Negus S.S., Mello N.K., and Bidlack J.M. k-opioid receptors are differentially labeled by arylacetamides and benzomorphans. Eur. J. Pharmacol. 485 (2004) 119-125
30. Saland K.E., Hillis L.D., Lange R.A., and Cigarroa J.E. Influence of morphine sulfate on cocaine-induced coronary vasoconstriction. Am. J. Cardiol. 90 (2002) 810-811
31. Schindler C.W. Cocaine and cardiovascular toxicity. Addict. Biol. 1 (1996) 31-47
32. Spampinato S., and Goldstein A. Immunoreactive dynorphin in rat tissues and plasma. Neuropeptides 3 (1983) 193-212
33. Tella S.R., Schindler C.W., and Goldberg S.R. Chlorisondamine, a non-competitive ganglionic blocker, antagonizes the cardiovascular effects of cocaine in conscious squirrel monkeys. Pharmacol. Res. 27 (1993) 233-239
34. Wollermann M., Benyhe S., and Simon J. The kappa-opioid receptor: Evidence for the different subtypes. Life Sci. 52 (1993) 599-611
35. Wong T.M., Lee A.Y., and Tai K.K. Effects of drugs interacting with opioid receptors during normal perfusion or ischemia and reperfusion in the isolated rat heart - an attempt to identify cardiac opioid receptor subtypes(s) involved in arrhythmogenesis. J. Mol. Cell. Cardiol. 22 (1990) 1167-1175
36. Wong T.M., Sheng J.Z., Wong N.S., and Tai K.K. Signal transduction in the cardiac k-receptor. Biol. Signals 4 (1995) 174-178
37. Woods J.H. Some thoughts on the relations between animal and human drug-taking. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 7 (1983) 577-584
38. Wu K.M., and Martin W.R. Cardiovascular and respiratory effects of an opioid agonist ethylketazocine and sigma agonist N-allylnormetazocine in acutely decerebrated dogs. Pharmacol. Biochem. Behav. 34 (1989) 405-411
39. Young G.A., and Khazan N. Self-administration of ketocyclazocine and ethylketocyclazocine by the rat. Pharmacol. Biochem. Behav. 19 (1983) 711-713